FDA
-
-
-
-
-
-
-
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
-
-
-
-
-
-
-
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks
-
-
-
-
-
-
-
Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
-
-
-
-
-
-
-
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
-
-
-
-
-
-
-
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds
-
-
-
-
-
-
-
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
-
-
-
-
-
-
-
Moleculin raises $6.5 million through warrant exercises
-
325,553 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

